Dry immunofluorescence quantitative method heparin binding protein (HBP) detection kit

Abstract

The invention provides a dry immunofluorescence quantitative method heparin binding protein (HBP) detection kit. The kit comprises a reagent strip, the reagent strip comprises absorbent paper, a nitrocellulose membrane and a sample pad, the absorbent paper is located at one end of the nitrocellulose membrane, the sample pad is located at the other end of the nitrocellulose membrane, and the nitrocellulose membrane is sequentially coated with a quality control C line, a detection T line and a fluorescent antibody solidus; a novel fluorescence labeling process, a sample pad treating fluid and afluorescence marker immobilization process are adopted to rapidly, accurately and quantitatively detect heparin binding protein HBP in human plasma with high sensitivity, so that the problems that labeled fluorescent substances are unstable and later process control is not facilitated are solved; meanwhile, the fluorescent antibody is immobilized on the nitrocellulose membrane instead of a specialfluorescent binding pad, so that the precision is remarkably improved on the basis of widening the storage conditions of the kit.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to view more

AI Technical Summary

Benefits of technology

This patented technology describes an assay that uses specific chemical agents called Hep B Phe proteins to detect certain types of molecules associated with inflammatory processes such as platelet aggregation or leukocyte activation during blood clotting. These techniques have potential applications across various fields including medical diagnosis, biological researches, environmental monitoring, etc., especially when combined together into one device.

Problems solved by technology

This patented technical problem addressed by the inventors relates to detecting biologics called liver binding proteins (LPA). These molecules bind strongly to calcium released into blood vessels during hemorrhaging caused by bleeding due to various causes like surgery or trauma. They were found to accumulate at sites where these damaged areas occur more frequently compared to normal ones. By measuring their concentrations over hours after injury, we could predict if any damage will develop quickly enough to trigger vasospasm causing fluid leaks.

Images